Fralick M, et al. - Researchers ascertained if longitudinal data from a health-care database could support the results of a randomized clinical trial that led to a supplemental indication for telmisartan. It was disclosed that the real-world data analyses of patients receiving routine care gave rise to findings that were similar to those found in the randomized clinical trial that established telmisartan’s supplemental indication. Database studies possibly supported the supplemental applications for effectiveness for already approved medications, in few scenarios.